The pharmaceutical glass tubing market is estimated to reach USD 15.2 billion in 2024. Sales are projected to reach USD 22.2 billion by 2034, with an anticipated CAGR of 3.9%.
Global Pharmaceutical Glass Tubing Market Assessment
| Attributes | Description |
|---|---|
| Estimated Global Pharmaceutical Glass Tubing Market Size (2024E) | USD 15.2 billion |
| Projected Global Pharmaceutical Glass Tubing Market Value (2034F) | USD 22.2 billion |
| Value-based CAGR (2024 to 2034) | 3.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Injectable drugs are increasingly required in oncology, diabetes, and autoimmune diseases. In diabetes care, insulin delivery via pen devices is sought to improve convenience for patients. Biologics and biosimilars are mostly delivered through injectable formulations due to their molecular structure.
These trends are likely to create healthy opportunities for healthcare providers in the injectable drug sector, especially for chronic disease treatment.
Principal Consultant
Injectable therapies are becoming more acceptable for patients, thanks to the development of prefilled syringes and self-injectable pens. It has been estimated that 40% of patients with chronic diseases prefer injectables due to their rapid onset of action.
These devices also improve compliance, especially in diabetes and autoimmune diseases. The increasing demand for injectables as an effective treatment modality in chronic diseases presents a key market opportunity for healthcare providers operating in innovative drug delivery systems.
Global demand for pharmaceutical glass tubing is closely linked to immunization experiences. Immunization programs such as DTP3, measles, Hepatitos have a wide coverage, with close to 200 countries enrolled in them.
Such large scale vaccination programs create substantial demand for products such as pharmaceutical glass tubing. The global immunization programs are only going to increase in the future, which will further boost demand.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
With the continuous increase in the elderly population in the United States and Europe, healthcare providers and policymakers are closely following the evolving needs of the elderly demographic.
The following trends show an increasing need for tailored healthcare solutions and vaccination programs to meet the unique needs of the elderly across countries. Understanding these market dynamics can help healthcare companies better position their products and services to serve this evolving patient population.
In Japan, 28% of the population is aged 65+ increasing the requirement for pharmaceuticals like injectable therapies. Common treatments include insulin for diabetes and biologics for rheumatoid arthritis, along with vaccinations for influenza, pneumococcal, and herpes zoster. Italy’s aging population (23%) relies on anticoagulants, osteoporosis treatments, and flu pneumococcal vaccines.
In Germany, 22% of the population requires chemotherapy agents and multiple sclerosis treatments, along with influenza and pneumococcal vaccinations. Other key markets with 20 to 22% elderly populations, focus on hormone treatments, cancer immunotherapies, and vaccinations, increasing demand for products like pharmaceutical glass tubing globally.
With the increasing demand for precision, safety, and sustainability in the pharmaceutical glass tubing market, prominent companies are exploring investments in progressive technologies. These include, but are not limited to,
Precision Engineering and Automation Increase Efficiency and Quality
Advanced automated glass forming machines improve production speed, reduce errors, and ensure compliance with USP Type I standards. CNC technology supports precise adjustments, producing defect-free tubing for complex formulations like biologics. These innovations lower operational costs and improve efficiency, offering manufacturers financial stability and growth potential.
Improved Glass Chemistry and Coatings Ensure Drug Safety and Reliability
Alkali-leach-resistant glass prevents contamination, meeting regulatory requirements and enhancing market appeal. Specialized surface coatings reduce scratches and breakage, which minimizes product waste and saves on logistics. This durability fuels demands-especially for high-value drugs positions them to capture premium pricing while increasing revenue streams.
Digital Quality Control Systems Increase Efficiency
The vision-based inspection system allows only quality tubes to reach the market, thereby reducing losses due to defects. Smart sensors maintain the standards of production, improving operational efficiency and consistency. These technologies lower overhead costs and help manufacturers meet strict quality requirements, thus making them more competitive.
Sustainability and Customization: Capturing Emerging Market Trends
Energy-efficient furnaces and glass formulations that are recyclable satisfy the global sustainability objectives of eco-conscious investors. Innovations in prefilled syringe tubing and cartridge-specific designs meet growing demand for injectable biologics and insulin. These advancements support premium pricing and enable market expansion, driving financial growth in the pharmaceutical glass tubing sector.
By investing in these technological advancements, companies can capitalize on the growing demand for precision, safety, and sustainability in pharmaceutical glass tubing, securing long-term economic benefits.
Quality Assured amid Rising Standards Hinder a Key Factor to Beat
The glass tubing used in the pharmaceutical industry has to strictly meet all the international quality standards, such as USP Type I, for total safety. Non-compliance could mean recalls, legal consequences, and loss of goodwill.
Such would be the case with Hospira's glass particulates-related recalls in 2023, which underlined financial and operational vulnerabilities linked to quality deviations. Indeed, manufacturers have to make intensive investments in precision processes and quality assurance systems to avoid these types of costly setbacks.
Inflated Costs and Disrupted Production Affect Profit Margins
This dependency on borosilicate glass exposes manufacturers to supply shortages and price fluctuations. Energy cost increases and supply chain disruptions add to the production-affecting issues. For example, a 2005 energy cost surge in Europe that doubled operational expenses saw some facilities forced to shut down or reduce capacity in 2022.
Balancing Efficiency with Sustainability Trend Demand Heavy Investments
Glass production requires 1,400°C to 1,600°C temperatures and consumes 4 -7 GJ per ton. Rising natural gas prices and stricter CO₂ regulations ass financial pressure as 1 ton of glass emits 1 ton of CO₂.
Transitioning into other fuels, such as hydrogen or electric furnaces, requires huge funding; hence, cost management is the key challenge for manufacturers in trying to keep their products at competitive prices.
Impact on Healthcare Providers and the Supply Chain on Growth
The above challenges thus raise the cost for health providers who depend on pharmaceutical glass tubing for vials, syringes, and packaging. Increased manufacturing costs may translate into higher prices of the products, delayed delivery, and strained supply chains. This directly affects the availability and affordability of critical drugs for patients worldwide.
Material-type segmentation in the pharmaceutical glass tubing market includes Type I, Type II, and Type III. Among these types, Type I glass is the most in-demand one and is primarily used for aqueous solutions.
Type I glass is dominant due to unmatched chemical resistance and allows drugs to be stable. This prevents leaching and will have compliance with stringent pharmaceutical standards. A few reasons for popularity include -
With the above-mentioned points and findings, the FMI analyst estimates the share value of Type I material type to be 38% in 2024. For instance, In October 2023, SCHOTT AG launched FIOLAX® Pro, a new type I borosilicate glass tubing. The company utilized green energy and secured funding for a climate-friendly glass melting tank, addressing trends in complex pharmaceuticals, sustainability, and digitalization.
Various applications like bottles, ampoules, vials, syringes, and cartridges are categorized in this segment. Vials dominate the pharmaceutical packaging market due to their versatility and durability. They are important in storing vaccines, biologics, and injectable drugs that require high standards of protection. Other reasons like-
Thus, vials gain popularity in the market due to the high demand for any drug in an injectable format in the biopharmaceutical industry. FMI analysts project the vial segment to hold a substantial market share in 2024 of 31%, reflecting the continued reliance on glass vials for safe and reliable drug storage and delivery.
Pharmaceutical glass tubes are commonly found in four neck diameters- up to 40 mm, 40 mm to 80 mm, 80 mm to 120 mm, and more than 120 mm. The 40 mm to 80 mm is the most widely used neck diameter in the market. Its popularity speaks for its wide usage in pharmaceutical vials and bottles.
It is a size that allows convenience in handling, precision in dosage, and aptness toward automated filing lines. As the demand is high, manufacturers and healthcare providers focus on this segment because it supports scalable manufacturing and profitability.
The section below mentions prominent countries with CAGR and key advances.
| Country | CAGR (2024 to 2034) |
|---|---|
| India | 5.9% |
| China | 4.8% |
| United Kingdom | 4.1% |
The United States pharmaceutical glass tubing market thrives on better healthcare infrastructure and strong pharmaceutical production. High demand originates due to biologics and vaccines that require premium quality and regulated-complaint glass tubing.
Technological innovations like precision-engineered tubing for drug delivery systems, further boost growth. However, competition from alternative materials and the push for sustainable solutions present challenges for manufacturers. The United States is estimated to report a share value of 22.4% in 2024.
For instance, in November 2024, Australia's audit office probed the Morrison government's USD 2 billion deal with the United States pharmaceutical giant Moderna. Local companies were overlooked as Moderna raced to meet its timeline while a spurned rival began shipping COVID-19 vaccines overseas.
India’s cost-efficient manufacturing and role as a global supplier of generics bolster its pharmaceutical glass tubing market. Government initiatives, such as boosting healthcare infrastructure and fostering pharmaceutical innovation create growth potential. Rising exports of vaccines and biologics further soars the demand.
The United Kingdom is strengthened by its established pharmaceuticals sector and biopharmaceuticals research and development focus. Demand for high-quality tubing aligns with innovation and stringent drug safety standards.
Although Brexit introduced supply chain complexities, supportive policies ensure market resilience. Investments in high-tech technologies and quality standards sustain the United Kingdom’s competitive edge in glass tubing manufacturing.
China’s pharmaceutical glass tubing market grows rapidly due to increasing domestic manufacturing and healthcare investments. Government initiatives encouraging innovation and expanding biologics with vaccine production drive demand.
With a large patient base and rising vaccine needs, manufacturers have huge opportunities. As a result, ensuring regulatory compliance and maintaining international quality standards are critical to long-term market success.
| Company | Key Developments |
|---|---|
| Corning | In November 2015, acquired Gerresheimer's glass tubing business in the United States and Italy, forming a joint venture to drive innovations. |
| Gerresheimer | In May 2024, acquired Bormioli Pharma Group, a major player in glass and plastic primary packaging. |
| Corning & SGD Pharma | In June 2023, established a joint venture to open a new glass tubing facility in India, leveraging Corning's technology. |
| Nipro | In July 2024, launched D2F (Direct-to-Fill) glass vials featuring Stevanato’s EZ-fill technology. |
| SCHOTT | In March 2023, SCHOTT announced a €75 million investment to expand its pharmaceutical glass production in India |
The section includes Type I, Type II, and Type III material types.
Pharmaceutical glass tubes come with their manufacture into 4 broad categories such as below 40 mm, 40 to 80 mm, 80 to 120 mm, and above 120 mm diameters.
Classified applications of pharmaceutical tubing are bottles, ampoules, vials, syringes, and cartridges amongst others.
Information about the leading countries of North America, Latin America, Western Europe, South Asia and Pacific, East Asia, and the Middle East and Africa is given.
It is anticipated to reach USD 15.2 billion in 2024.
The market is set to rise at a 3.9% CAGR through 2034.
The pharmaceutical glass tubing market is projected to reach USD 22.2 billion by 2034.
Type I dominates the market with a 38% share value in 2024.
The United States holds the highest share value of 22.4% in the market.
Explore Packaging Insights
View Reports
Pharmaceutical Glass Tubing Market
